###begin article-title 0
###xml 75 80 <span type="species:ncbi:9606">women</span>
The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer - a multicenter study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 282 290 <span type="species:ncbi:9606">patients</span>
The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
In the present study 38 cases of cancer related death and a median time of follow-up (range) of 55.3 (0.4-175.8) months was observed. IL1RN 2/2 (homozygous mutant) gene polymorphism was associated with shortened disease free and overall survival in a univariate (p = 0.001 and p = 0.01, respectively) and multivariate analysis (p = 0.002, Odds Ratio [95% Confidence Interval] = 3.6 [1.6-8.0] and p = 0.05, Odds Ratio = 3.0 [1.1-9.3], respectively). Presence of the homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the multivariate analysis. No association was observed between all possible haplotype combinations and overall survival.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
The interleukin-1 (IL-1) family consists of the cytokines, IL-1alpha (IL-1a), IL-1beta (IL-1b) and a specific receptor antagonist (IL-1RA) [1]. IL-1a and IL-1b are involved in various physiological and patho-physiological processes such as modulating the host response to microbial invasion, inflammation, and tissue injury [2]. IL-1RA neutralizes IL-1 action by binding to the IL-1 receptors (IL-1RI and IL-1RII) [3].
###end p 11
###begin p 12
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 365 374 365 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 340 345 <span type="species:ncbi:9606">human</span>
In addition to its role in inflammatory processes, IL-1 has been extensively studied in various malignancies. Expression of IL-1 has been described in breast cancer tissue [4,5] as well as several other tumor tissues [6,7]. Its production and release by tumor cells results in an autocrine and paracrine induction of prometastatic genes in human breast cancer [8]. In vitro studies reported IL-1 to be crucially involved in cell survival, proliferation, and angiogenesis [6]. Recent studies suggested that IL-1 was associated with more aggressive forms of breast cancer [9,10].
###end p 12
###begin p 13
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1A</italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1B</italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1RN</italic>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 256 265 256 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 269 277 269 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A </italic>
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-B </italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
The IL-1 gene cluster on chromosome 2q14.2 comprises 3 related genes within a 430-kilobase (kb) region, IL-1A, IL-1B, and IL-1RN, which encode the pro-inflammatory cytokines IL-1a, IL-1b, and their endogenous receptor antagonist IL-1RA, respectively [11]. In vitro and in vivo studies demonstrated that IL1-A and IL1-B gene polymorphisms [12,13] corresponded with altered IL-1a and IL-1b protein expression, respectively [12,14]. Regarding the IL1 receptor antagonist, the IL1RN mutant allele 2 has been repeatedly associated with changes of the IL-1RA protein expression [15,16].
###end p 13
###begin p 14
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
IL-1 polymorphisms have been investigated in a variety of malignancies. They were associated with an increased risk for ovarian [17], gastric [18], lung [19], and prostate cancer [20]. With respect to breast cancer, two recent studies demonstrated an association between IL-1 polymorphisms and increased risk for the disease [21,22].
###end p 14
###begin p 15
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
While other interleukin polymorphisms have been extensively studied as prognostic markers in breast cancer patients [23-25] little is known about the prognostic value of IL-1 gene polymorphisms. In one study comprising Tunisian patients with breast cancer the IL1A TT (homozygous mutant) genotype was associated with impaired prognosis in patients with breast cancer [26].
###end p 15
###begin p 16
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, we are the first to investigate the prognostic value of gene polymorphisms within the IL-1 family in Caucasian patients with breast cancer.
###end p 16
###begin title 17
Methods
###end title 17
###begin p 18
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Two-hundred-sixty-two consecutive patients with breast cancer treated between 1999 and 2001 at the Departments of Obstetrics and Gynecology, Martin-Luther-University Medical School, Halle-Wittenberg, Germany and Medical University of Vienna, Vienna, Austria, were included in our study. All of the participating patients were of Caucasian origin and signed written consent. Approval for this study was obtained by the Institutional Review Boards at the Martin-Luther-University Medical School, Halle-Wittenberg, Germany and the Medical University of Vienna, Vienna, Austria.
###end p 18
###begin p 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">Patients</span>
Patients' data was collected by reviewing patients' files. Of note, family history of breast cancer was documented only in very few cases and therefore not included in our analysis. Histological staging of breast cancer was performed according to the current classification of the International Union Against Cancer (UICC). All cases were reviewed by an experienced pathologist, blinded to patients' clinical data. Patients received surgery, chemotherapy, radiotherapy, and endocrine therapy by standard protocols. National guidelines were followed according to St. Gallen recommendations in the respective years.
###end p 19
###begin p 20
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
DNA was extracted from patients' blood. Pyrosequencing and polymerase chain reaction (PCR) were performed according to established protocols as described previously [27].
###end p 20
###begin p 21
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 632 637 632 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 672 678 672 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 942 949 <span type="species:ncbi:9606">patient</span>
After testing for normality using Kolmogorov-Smirnov test, values are given as mean (standard deviation [SD]) or median (range), where appropriate. Hardy-Weinberg equilibrium was tested by chi-square tests comparing observed and expected haplotype frequencies. Associations between polymorphisms and clinicopathological parameters were calculated by chi-square tests - results are given as p-value and Odds Ratio (OR) (95% Confidence Interval [95%CI]). Due to multiple testing Bonferroni-Holmes adjustment was performed. Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (</= 50 years vs. > 50 years).
###end p 21
###begin p 22
###xml 681 687 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 761 766 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 775 780 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 791 797 791 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
Survival probabilities were calculated by the product limit method of Kaplan and Meier. Differences between groups were tested using the log-rank test. The results were analyzed for the endpoint of disease free and overall survival. Survival times of patients without any evidence of recurrent disease or still alive at the time of last follow-up were censored with the last follow-up date. A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).
###end p 22
###begin p 23
Haplotype frequencies were calculated by using SAS/Genetics software. Association between haplotypes and breast cancer survival was calculated using a Cox regression model treating each haplotype as an independent continuous variable.
###end p 23
###begin p 24
We used the software SAS System (Version 9.1 SAS Institute Inc., Cary, NC) and SPSS (SPSS 11.0, SPSS Inc. Chicago, IL) for statistical analysis. Two-sided p-values </= 0.05 were considered statistically significant.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 505 510 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' characteristics are given in Table 1 (Additional file 1). Genotype and allele frequencies of the four investigated IL-1 gene polymorphisms are given in Table 2 (Additional file 1). As previously published genotype distribution of all investigated gene polymorphisms was in Hardy-Weinberg equilibrium [28]. The four investigated polymorphisms were all in linkage disequilibrium (IL1A -889 and IL1B -511: p = 0.0001, Lewontin's D' = 0.5; IL1B -511 and IL1B +3953: p < 0.0001, Lewontin's D' = 0.7; IL1B +3953 and IL1RN: p = 0.004, Lewontin's D' = 0.6).
###end p 26
###begin p 27
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 357 364 <span type="species:ncbi:9606">patient</span>
IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.
###end p 27
###begin p 28
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 557 563 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
Survival analysis were calculated by performing univariate Kaplan-Meier analysis and multivariate Cox-Regression models to correct for established clinicopathological parameters. Results are presented in Table 3 (Additional file 1). In a univariate Kaplan-Meier analysis only IL1RN gene polymorphisms was associated with disease free survival (Figure 1.), whereas IL1A -889, IL1B -+3953, and IL1RN (Figure 2.) were associated with overall survival. After correcting for established clinicopathological parameters in a multivariate Cox-Regression model, the IL1RN gene polymorphism was independently associated with shortened disease free and overall survival.
###end p 28
###begin p 29
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Disease free survival of patients with breast cancer broken down by the <italic>IL1RN </italic>polymorphism</bold>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Disease free survival of patients with breast cancer broken down by the IL1RN polymorphism. P denotes the log-rank test value.
###end p 29
###begin p 30
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overall survival of patients with breast cancer broken down by the <italic>IL1RN </italic>polymorphism</bold>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Overall survival of patients with breast cancer broken down by the IL1RN polymorphism. P denotes the log-rank test value.
###end p 30
###begin p 31
Furthermore, the combined effect of the four gene polymorphisms on breast cancer survival was investigated by haplotype analysis (Additional file - Table 4). No significant associations between haplotypes and overall survival were observed.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
In the present study, the IL1RN long/2 gene polymorphism was independently associated with an unfavourable prognosis in breast cancer patients, while presence of the mutant alleles of IL1A -889 and IL1B +3953 were only associated with a shortened overall survival in a univariate analysis. These findings are in line with a series of studies that have found interleukin gene polymorphisms to be associated with shortened overall survival in breast cancer patients [23,25].
###end p 33
###begin p 34
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
This is biologically plausible, as mutations of IL1A -889 and IL1B +3953 are thought to lead to increased IL-1 production [12,14,15]. In comparison, the mutant IL1RN allele has been reported to modify the binding on the IL1-receptor, leading to a worse inhibition of the IL-1a and IL-1b binding and subsequently to an increased IL-1 production [29]. This might result in an unfavourable proinflammatory status and enhanced tumor aggressiveness, which is likely to result in a shortened survival.
###end p 34
###begin p 35
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 162 167 <span type="species:ncbi:9606">human</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
In addition to its potential as a prognostic marker, particularly IL1RN is of increasing interest with regard to therapeutic implications. Recently a recombinant human IL-1 receptor antagonist, has been approved to block the proinflammatory effects of IL-1 in patients with rheumathoid arthritis [30]. Experimental data based on mouse models support the hypothesis that an IL-1 receptor antagonist might also work as a therapeutic agent in neoplasms [30,31].
###end p 35
###begin p 36
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 980 985 980 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 994 999 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B </italic>
Of note, the exact mechanisms by which these four polymorphisms exert their effects on IL-1 levels remain still unclear to date. In the present investigation, we focused on the evaluation of IL-1 gene polymorphisms, and did not plan to investigate serum levels of the IL-1 cytokines. Interestingly, IL1RN was the only of three polymorphisms that remained significant in the multivariate model, which was performed to correct for potential confounders. Despite this consistent association between IL1RN and overall survival in a univariate and multivariate analysis, it has to be considered that seven variables were included in the multivariate analysis with only 38 events observed. The high number of variables was included in the multivariate model as this is the only way to evaluate an independent association between the respective gene polymorphism and overall survival. In that case, however, a random finding can not be completely ruled out. The other two polymorphisms, IL1A -889 and IL1B +3953, were only associated with shortened survival in a univariate survival analysis. Therefore, it can not be ruled out that these associations might result from unequal distribution of well known prognostic factors, such as tumor stage, lymph node involvement or tumor grade.
###end p 36
###begin p 37
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
Of note, it was not feasible to evaluate the association between IL-1 gene polymorphisms and family history of breast cancer as this information was missing in the majority of patients. Furthermore, we were unable to investigate the association between IL-1 gene polymorphisms and distant metastases because of the limited number of events (4 patients with distant metastases).
###end p 37
###begin p 38
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
As all four IL-1 gene polymorphisms were in linkage disequilibrium, we performed a haplotype survival analysis to investigate whether there is a high risk haplotype combination. Interestingly, we were not able to identify such a high risk haplotype combination, which might be caused by the relatively high number of variables (n = 16) compared to the number of events (n = 38 cancer related deaths).
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 453 458 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 564 570 564 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1RN </italic>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
IL-1 has been reported to be crucially involved in cell survival, proliferation, and angiogenesis in cancer cells [6]. Moreover IL-1 secretion seems to be associated with a more aggressive form of breast cancer [9,10]. IL-1 gene polymorphisms were reported to be associated with an increased risk of breast cancer [21,22]. They are thought to increase IL-1 levels subsequently contributing to a proinflammatory environment. All of the four investigated IL-1 gene polymorphisms have been demonstrated to correspond with altered IL-1 protein expression [12-16]. The IL1RN gene polymorphism might be of prognostic value as carriage of the two mutant alleles was independently associated with shortened disease free and overall survival in Caucasian patients with breast cancer.
###end p 40
###begin title 41
Competing interests
###end title 41
###begin p 42
The authors declare that they have no competing interests.
###end p 42
###begin title 43
Authors' contributions
###end title 43
###begin p 44
CG was critically involved in designing the study, statistical analysis, and drafted the manuscript. LH conceived of the study, participated in the design of the study and helped draft the manuscript. EK carried out molecular genetic studies, contributed to acquisition of data, and critically revised the manuscript. GH was involved in design of the study, statistical analysis, and revision of the methods section of the manuscript. SP was involved in acquisition of the data, and interpretation of the data. RZ participated in primer selection, provided biomolecular expertise, carried out molecular analysis, and helped with statistical analysis. HK partially conceived of the study and participated in its design and coordination. AR was substantially involved in the design of the study and drafting the manuscript. All authors read and approved to the final manuscript.
###end p 44
###begin title 45
Pre-publication history
###end title 45
###begin p 46
The pre-publication history for this paper can be accessed here:
###end p 46
###begin p 47

###end p 47
###begin title 48
Supplementary Material
###end title 48
###begin title 49
Additional file 1
###end title 49
###begin p 50
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tables</bold>
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1 </italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1 </italic>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
Tables. Table 1. Characteristics in patients with breast cancer. Table 2. Genotype and allele frequencies of the four investigated IL1 gene polymorphisms in breast cancer patients. Table 3. Survival analysis of IL1 gene polymorphisms and prognostic covariates in patients with breast cancer. Table 4. Association between interleukin-1 haplotypes and overall survival of patients with breast cancer.
###end p 50
###begin p 51
Click here for file
###end p 51
###begin article-title 52
Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma
###end article-title 52
###begin article-title 53
Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist
###end article-title 53
###begin article-title 54
###xml 73 78 <span type="species:ncbi:9606">human</span>
Interleukin-1 beta enhances interleukin-1 receptor antagonist content in human somatotroph adenoma cell cultures
###end article-title 54
###begin article-title 55
###xml 162 167 <span type="species:ncbi:9606">human</span>
Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines
###end article-title 55
###begin article-title 56
###xml 35 40 <span type="species:ncbi:9606">human</span>
Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist
###end article-title 56
###begin article-title 57
IL (Interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas
###end article-title 57
###begin article-title 58
###xml 64 69 <span type="species:ncbi:9606">human</span>
Molecular analysis of constitutive IL-1alpha gene expression in human melanoma cells: autocrine stimulation through NF-KB activation by endogenous IL-1alpha
###end article-title 58
###begin article-title 59
Cancer cell-derived interleukin 1 alpha contributes to autocrine and paracrine induction of prometastatic genes in breast cancer
###end article-title 59
###begin article-title 60
Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity
###end article-title 60
###begin article-title 61
###xml 60 65 <span type="species:ncbi:9606">human</span>
Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype
###end article-title 61
###begin article-title 62
Biologic basis for interleukin-1 in disease
###end article-title 62
###begin article-title 63
###xml 25 30 <span type="species:ncbi:9606">human</span>
TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro
###end article-title 63
###begin article-title 64
###xml 40 45 <span type="species:ncbi:9606">human</span>
Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta)
###end article-title 64
###begin article-title 65
A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals
###end article-title 65
###begin article-title 66
###xml 30 35 <span type="species:ncbi:9606">human</span>
Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism
###end article-title 66
###begin article-title 67
###xml 48 53 <span type="species:ncbi:9606">human</span>
Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis
###end article-title 67
###begin article-title 68
Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer
###end article-title 68
###begin article-title 69
Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population
###end article-title 69
###begin article-title 70
Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene
###end article-title 70
###begin article-title 71
Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
###end article-title 71
###begin article-title 72
###xml 123 128 <span type="species:ncbi:9606">women</span>
Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women
###end article-title 72
###begin article-title 73
Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population
###end article-title 73
###begin article-title 74
Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma
###end article-title 74
###begin article-title 75
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis
###end article-title 75
###begin article-title 76
The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype
###end article-title 76
###begin article-title 77
Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma
###end article-title 77
###begin article-title 78
A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis
###end article-title 78
###begin article-title 79
###xml 94 99 <span type="species:ncbi:9606">women</span>
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women
###end article-title 79
###begin article-title 80
###xml 16 21 <span type="species:ncbi:9606">human</span>
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat
###end article-title 80
###begin article-title 81
Anakinra
###end article-title 81
###begin article-title 82
A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development
###end article-title 82
###begin article-title 83
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 94 103 <span type="species:ncbi:10090">nude mice</span>
Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice
###end article-title 83

